Voyager CEO Al Sandrock views partnerships as more than just revenue. He emphasizes that strong scientific collaborations are invaluable because direct interaction between partner scientists accelerates learning and overall progress for both organizations. This intellectual cross-pollination is a key, often overlooked, benefit of partnering out platform technology.

CHOP's tech transfer function is twofold. It not only licenses its own discoveries ("outbound") but also facilitates collaborations where companies leverage CHOP's expertise for their existing pipelines ("inbound"). This positions the research institution as both an IP source and a strategic research partner.

A successful acquisition strategy goes beyond the highest bid. It involves 'thinking like the molecule'—evaluating which buyer has the specific expertise, capabilities, and cultural alignment to best steward the asset's development. This reframes M&A from a financial transaction to a decision about the asset's future.

To speed up IP licensing from a university, founders should avoid advisors known for aggression. Instead, hire an experienced, solution-oriented advisor who already has a good relationship with the tech transfer office. They won't waste time creating bad will over impossible demands.

Zev Sunleaf, VP of Tech Transfer at CHOP, entered the field with a business degree, not a science Ph.D. His experience co-founding startups based on university research provided the necessary expertise, demonstrating an alternative, entrepreneurial route into a traditionally science-heavy profession.

A key skill in building a deep tech team is identifying individuals who can bridge the gap between complex science and business reality. These "translators" can articulate highly technical concepts in plain English, clarifying clinical relevance and commercial viability for decision-makers.

A university's Tech Transfer Office (TTO) should not be viewed as an opponent. Michal Preminger notes that nearly every spinout eventually returns to the TTO asking for a favor, such as a milestone extension or access to new IP. A positive initial negotiation is crucial for this future relationship.

CHOP's Zev Sunleaf reveals that ensuring a partner has the capability and commitment to develop a technology is a more difficult negotiation point than the financial details. This prioritizes patient impact and long-term success over immediate revenue, a key insight for dealmakers.

Biotech assets have both value ("cheese") and risks ("holes"). Kainova's CEO argues the key to successful deal-making is managing multiple parallel conversations. This lets you identify partners focused on the asset's potential and close when they are ready, rather than getting bogged down by those fixated on the risks.